Antiproliferative, Apoptotic, and Autophagic Activity of Ranibizumab, Bevacizumab, Pegaptanib, and Aflibercept on Fibroblasts: Implication for Choroidal Neovascularization

Antiproliferative, Apoptotic, and Autophagic Activity of Ranibizumab, Bevacizumab, Pegaptanib, and Aflibercept on Fibroblasts: Implication for Choroidal Neovascularization

Purpose. Choroidal neovascularization (CNV) is one of the most common complications of retinal diseases accompanied by elevated secretion of vascular endothelial growth factor (VEGF). Intravitreal anti-VEGFs (ranibizumab, bevacizumab, pegaptanib, and aflibercept) can suppress neovascularization, dec...

Full description

Bibliographic Details
Main Authors:	Lyubomyr Lytvynchuk, Andrii Sergienko, Galina Lavrenchuk, Goran Petrovski
Format:	Article
Language:	English
Published:	Hindawi Limited 2015-01-01
Series:	Journal of Ophthalmology
Online Access:	http://dx.doi.org/10.1155/2015/934963

Similar Items

Comparison of subconjunctivally injected bevacizumab, ranibizumab, and pegaptanib for inhibition of corneal neovascularization in a rat model
by: Cem Küçükerdönmez, et al.
Published: (2013-04-01)

Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization
by: Jia-Kang Wang, et al.
Published: (2018-09-01)

Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
by: Maria Waizel, et al.
Published: (2017-05-01)

Early shift from ranibizumab to aflibercept for resistant pigment epitelial detachment in classical choroidal neovascularization
by: Sever Ozkan, et al.
Published: (2017-10-01)

Intravitreal aflibercept for choroidal neovascularization secondary to angioid streaks in a non-responder to intravitreal ranibizumab
by: Makri OE, et al.
Published: (2018-09-01)

Long-term outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
by: Ki Won Jin, et al.
Published: (2021-07-01)

Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization
by: Tariq Al-Debasi, et al.
Published: (2017-04-01)

Choroidal Osteoma and Secondary Choroidal Neovascularization Treated with Ranibizumab
by: Almila Sarıgül Sezenöz, et al.
Published: (2017-08-01)

Comparison of Intravitreal Aflibercept and Ranibizumab for Treatment of Myopic Choroidal Neovascularization: One-Year Results—A Retrospective, Comparative Study
by: Burak Erden, et al.
Published: (2019-01-01)

Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab
by: Lim LS, et al.
Published: (2015-09-01)

Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
by: David R. Griffin, et al.
Published: (2014-01-01)

Aflibercept Treatment Leads to Vascular Abnormalization of the Choroidal Neovascularization
by: Adam Wylęgała, et al.
Published: (2018-01-01)

Result of intravitreal aflibercept injection for myopic choroidal neovascularization
by: Shih-Lin Chen, et al.
Published: (2021-09-01)

Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration
by: Partha Biswas, et al.
Published: (2011-01-01)

Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization
by: Ellabban AA, et al.
Published: (2012-05-01)

Peripapillary Choroidal Neovascular Membrane Secondary to Sarcoidosis-Related Panuveitis: Treatment with Aflibercept and Ranibizumab with a 50-month Follow-Up
by: Artemis Matsou, et al.
Published: (2021-04-01)

Single intravitreal ranibizumab for myopic choroidal neovascularization
by: Shatriah I, et al.
Published: (2011-08-01)

Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis
by: Miura M, et al.
Published: (2013-08-01)

Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
by: Mohamed A. Hamid, et al.
Published: (2021-04-01)

Photodynamic monotherapy or combination treatment with intravitreal triamcinolone acetonide, bevacizumab or ranibizumab for choroidal neovascularization associated with pathological myopia
by: Pukhraj Rishi, et al.
Published: (2011-01-01)

Intravitreal aflibercept in neovascular age-related macular degeneration previously treated with ranibizumab
by: Rachel Hui Fen Lim, et al.
Published: (2017-03-01)

Intravitreal aflibercept treatment for choroidal neovascularization secondary to laser pointer
by: Ali Keles, et al.
Published: (2020-01-01)

Intravitreal bevacizumab for management of choroidal osteoma without choroidal neovascularization
by: Farhad Fazel Najafabadi, et al.
Published: (2015-01-01)

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
by: Pessoa B, et al.
Published: (2021-01-01)

The outcomes of aflibercept therapy in patients with age-related macular degeneration resistant to bevacizumab or ranibizumab
by: Erkan Unsal, et al.
Published: (2018-12-01)

Intravitreal ranibizumab and bevacizumab therapy for choroidal neovascularization in age-related macular degeneration with extensive pre-existing geographic atrophy
by: Miguel Hage Amaro, et al.
Published: (2012-08-01)

Comparison of ranibizumab and bevacizumab in neovascular age-related macular degeneration
by: Huseyin Serdarogullari, et al.
Published: (2014-05-01)

A comparative debate on the various anti-vascular endothelial growth factor drugs: Pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin)
by: Nagpal Manish, et al.
Published: (2007-01-01)

Comparison of the effectiveness of various protocols for the transition to aflibercept with tachyphylaxis for ranibizumab in patients with neovascular AMD
by: A. N. Kulikov, et al.
Published: (2018-11-01)

Intravitreal ranibizumab for treatment of choroidal neovascularization secondary to a bilateral choroidal osteoma
by: Sidra Zafar, et al.
Published: (2016-12-01)

Intravitreal aflibercept for management of subfoveal choroidal neovascularization secondary to angioid streaks
by: Ebru Esen, et al.
Published: (2015-01-01)

Intravitreal aflibercept for choroidal neovascularization associated with chorioretinitis: a pilot study
by: Korol AR, et al.
Published: (2017-07-01)

Myopic Choroidal Neovascularization Membranes Treated With Ranibizumab in Colombian Population
by: Hernan Andres Rios, et al.
Published: (2017-01-01)

Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization Secondary to Endogenous Endophthalmitis
by: Shwu-Jiuan Sheu
Published: (2009-11-01)

MYOPIC CHOROIDAL NEOVASCULAR MEMBRANES TREATED WITH RANIBIZUMAB IN COLOMBIAN POPULATION
by: Hernan Andres Rios, et al.
Published: (2017-06-01)

Drastic effect of ranibizumab on choroidal neovascularization in idiopathic angioid streaks
by: Umit Yolcu, et al.
Published: (2015-08-01)

Intravitreal ranibizumab for the treatment of choroidal neovascularization secondary to ocular toxoplasmosis
by: Neeraj Pandey, et al.
Published: (2013-01-01)

Intravitreal ranibizumab for the treatment of choroidal neovascularization secondary to ocular toxoplasmosis
by: Nikunj J Shah, et al.
Published: (2011-01-01)

Choroidal osteoma with choroidal neovascular membrane: Successful treatment with intravitreal bevacizumab
by: Neeraj Pandey, et al.
Published: (2010-09-01)

Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema
by: Alsaedi NG, et al.
Published: (2021-07-01)

Cannot write session to /tmp/vufind_sessions/sess_5c4o7lfm6ktcpkef4d86sjrmp6